Hasil Pencarian - Barry A. Singer

  • Menampilkan 1 - 6 hasil dari 6
Perbaiki Hasil
  1. 1
    Initiating oral fingolimod treatment in patients with multiple sclerosis

    Initiating oral fingolimod treatment in patients with multiple sclerosis oleh Barry A. Singer

    Diterbitkan 2013-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    The role of natalizumab in the treatment of multiple sclerosis: benefits and risks

    The role of natalizumab in the treatment of multiple sclerosis: benefits and risks oleh Barry A. Singer

    Diterbitkan 2017-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study

    Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, doub... oleh Annette Wundes, Sibyl Wray, Ralf Gold, Barry A. Singer, Elzbieta Jasinska, Tjalf Ziemssen, Jerome de Seze, Pavle Repovic, Hailu Chen, Jerome Hanna, Jordan Messer, Catherine Miller, Robert T. Naismith

    Diterbitkan 2021-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing–Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study

    Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing–Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study oleh Barry A. Singer, Sibyl Wray, Mark Gudesblatt, Barbara Bumstead, Tjalf Ziemssen, Ashley Bonnell, Matthew Scaramozza, Seth Levin, Mathura Shanmugasundaram, Hailu Chen, Jason P. Mendoza, James B. Lewin, Sai L. Shankar

    Diterbitkan 2024-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study

    Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study oleh Alasdair J. Coles, Anat Achiron, Anthony Traboulsee, Barry A. Singer, Carlo Pozzilli, Celia Oreja-Guevara, Gavin Giovannoni, Giancarlo Comi, Mark S. Freedman, Tjalf Ziemssen, Debora Shiota, Andreea M. Rawlings, Alana T. Wong, Magdalena Chirieac, Xavier Montalban

    Diterbitkan 2023-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies

    Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of th... oleh Antonio Bertolotto, Rafael Arroyo, Elisabeth G. Celius, Giancarlo Comi, Eva Kubala Havrdova, William David Honeycutt, Samuel F. Hunter, Guillermo Izquierdo, Barbara Kornek, Tamara Miller, Dimos D. Mitsikostas, Barry A. Singer, Tjalf Ziemssen, Luke Chung, Nadia Daizadeh, Salman Afsar, Lobat Hashemi, Peter Senior

    Diterbitkan 2020-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: